BIOMAT Database Logo BIOMAT Database Logo

Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay. 1996

J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
Division of Retrovirology, Walter Reed Army Institute of Research, Rockville, Maryland 20850, USA.

Classification of human immunodeficiency virus type 1 (HIV-1) by neutralization serotype may be important for the design of active and passive immunization strategies. Neutralizing antibody serotyping is hindered by the lack of standard reagents and assay format, and by the weak activity of many individual sera. To facilitate cross-clade neutralization analysis, we used an infectivity reduction assay (IRA) and selected clade-specific serum (or plasma) pools from subjects infected with clade B and E HIV-1, respectively. Several serum pools were utilized; some were selected for strong neutralizing activity against intraclade viruses and others were derived from conveniently available samples. Against a panel of 51 clade B and E viruses, serum pools displayed strong neutralization of most intraclade viruses and significantly diminished cross-clade neutralization. Results were confirmed against a blinded panel of 20 viruses. The data indicate that the phylogenetic classification of virus subtypes B and E corresponds to two distinct neutralization serotypes. This approach to neutralizing antibody serotyping may be useful in defining the antigenic relationship among viruses from other clades.

UI MeSH Term Description Entries
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012703 Serotyping Process of determining and distinguishing species of bacteria or viruses based on antigens they share. Serotypings
D015699 HIV Envelope Protein gp120 External envelope protein of the human immunodeficiency virus which is encoded by the HIV env gene. It has a molecular weight of 120 kDa and contains numerous glycosylation sites. Gp120 binds to cells expressing CD4 cell-surface antigens, most notably T4-lymphocytes and monocytes/macrophages. Gp120 has been shown to interfere with the normal function of CD4 and is at least partly responsible for the cytopathic effect of HIV. Envelope Glycoprotein gp120, HIV,HTLV-III gp120,env Protein gp120, HIV,gp120(HIV),HIV Envelope Glycoprotein gp120,gp120 Envelope Glycoprotein, HIV,HTLV III gp120,gp120, HTLV-III
D019302 HIV Envelope Protein gp160 An envelope protein of the human immunodeficiency virus that is encoded by the HIV env gene. It has a molecular weight of 160,000 kDa and contains numerous glycosylation sites. It serves as a precursor for both the HIV ENVELOPE PROTEIN GP120 and the HIV ENVELOPE PROTEIN GP41. Envelope Glycoprotein gp160, HIV,HTLV-III gp160,env Protein gp160, HIV,gp160(HIV),HIV Envelope Glycoprotein gp160,gp160 Envelope Glycoprotein, HIV,HTLV III gp160,gp160, HTLV-III

Related Publications

J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.
January 2016, AIDS research and human retroviruses,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
Generation of neutralizing activity against human immunodeficiency virus type 1 in serum by antibody gene transfer.
September 2002, Journal of virology,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
A cytopathic infectivity assay of human immunodeficiency virus type 1 in human primary macrophages.
May 1996, Journal of virological methods,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
Vertical transmission of human immunodeficiency virus type 1: autologous neutralizing antibody, virus load, and virus phenotype.
June 1995, The Journal of pediatrics,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1.
December 1994, AIDS research and human retroviruses,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
Human immunodeficiency virus type 1 superinfection occurs despite relatively robust neutralizing antibody responses.
December 2008, Journal of virology,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection.
June 2007, Journal of virology,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
An international collaborative study on foot and mouth disease virus assay methods. 1. Virus infectivity and neutralizing antibody assays.
October 1984, Journal of biological standardization,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
Comparison of saliva and serum for human immunodeficiency virus type 1 antibody testing in Uganda using a rapid recombinant assay.
November 1996, Clinical and diagnostic laboratory immunology,
J R Mascola, and M K Louder, and S R Surman, and T C Vancott, and X F Yu, and J Bradac, and K R Porter, and K E Nelson, and M Girard, and J G McNeil, and F E McCutchan, and D L Birx, and D S Burke
[Neutralizing antibodies and human immunodeficiency virus type 1 (HIV-1) infection].
February 2011, Virologie (Montrouge, France),
Copied contents to your clipboard!